文献速递糖尿病

β细胞细胞外囊泡PD-L1作为CD8+ T细胞活性的新型调节因子及1型糖尿病演变过程中的生物标志物

Beta cell extracellular vesicle PD-L1 as a novel regulator of CD8+ T cell activity and biomarker during the evolution of type 1 diabetes.
PubMed 文献 · Diabetologia · 2024-11-07

研究提出1型糖尿病炎症环境增加β细胞细胞外囊泡(EV)携带的PD-L1,EV PD-L1可结合PD-1并抑制CD8+ T细胞增殖与细胞毒性;在胰岛自身抗体阳性个体中血浆EV PD-L1升高,且与循环C肽正相关,提示其可能保护残余β细胞功能。

要点

  • IFN-α或IFN-γ处理24小时使β细胞EV PD-L1货物增加两倍,而EV数量未相应增加。
  • β细胞EV PD-L1呈剂量依赖性结合PD-1,并抑制小鼠CD8+ T细胞增殖与细胞毒性。
  • 胰岛自身抗体阳性个体血浆EV PD-L1升高,尤其单自身抗体阳性者,且与循环C肽正相关。

核心结论

  • IFN暴露增加β细胞EV表面的PD-L1,EV PD-L1结合PD-1并抑制CD8+ T细胞增殖与细胞毒性。
  • 胰岛自身抗体阳性个体循环EV PD-L1高于非糖尿病对照个体,且在不同1型糖尿病进展阶段与残余C肽相关。
  • 这些发现提示EV PD-L1可能参与1型糖尿病进展和残余β细胞功能的异质性,并提出EV PD-L1或可被利用来抑制免疫介导的β细胞死亡的可能性。

研究设计与样本

  • 研究使用β细胞系和人胰岛,以促炎细胞因子处理模拟1型糖尿病促炎微环境。
  • EV通过超速离心或尺寸排阻色谱法分离,并用免疫印迹、流式细胞术和ELISA分析。
  • 通过竞争结合实验和体外功能实验评估EV PD-L1结合PD-1及抑制NOD CD8+ T细胞的能力。
  • 在胰岛自身抗体阳性个体或新发1型糖尿病个体血浆中检测EV和可溶性PD-L1,并与非糖尿病对照个体比较。

主要发现

  • PD-L1蛋白在细胞内与四跨膜蛋白相关蛋白共定位,并可在β细胞EV表面检测到。
  • IFN-α或IFN-γ处理24小时诱导EV PD-L1货物增加两倍,而EV数量无相应增加。
  • IFN暴露主要增加β细胞EV表面的PD-L1表达,β细胞EV PD-L1呈剂量依赖性结合PD-1的能力。
  • 功能实验证明β细胞EV PD-L1对小鼠CD8+ T细胞的增殖和细胞毒性有特异性抑制作用。
  • 血浆EV PD-L1水平在自身抗体阳性个体中升高,尤其在单自身抗体阳性者中;在自身抗体阳性或已患1型糖尿病个体中,血浆EV PD-L1与循环C肽正相关,而在对照个体中无此相关性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Surviving beta cells in type 1 diabetes respond to inflammation by upregulating programmed death-ligand 1 (PD-L1) to engage immune cell programmed death protein 1 (PD-1) and limit destruction by self-reactive immune cells. Extracellular vesicles (EVs) and their cargo can serve as biomarkers of beta cell health and contribute to islet intercellular communication. We hypothesised that the inflammatory milieu of type 1 diabetes increases PD-L1 in beta cell EV cargo and that EV PD-L1 may protect beta cells against immune-mediated cell death. METHODS: Beta cell lines and human islets were treated with proinflammatory cytokines to model the proinflammatory type 1 diabetes microenvironment. EVs were isolated using ultracentrifugation or size exclusion chromatography and analysed via immunoblot, flow cytometry and ELISA. EV PD-L1 binding to PD-1 was assessed using a competitive binding assay and in vitro functional assays testing the ability of EV PD-L1 to inhibit NOD CD8+ T cells. Plasma EV and soluble PD-L1 were assayed in the plasma of islet autoantibody-positive (Ab+) individuals or individuals with recent-onset type 1 diabetes and compared with levels in non-diabetic control individuals. RESULTS: PD-L1 protein co-localised with tetraspanin-associated proteins intracellularly and was detected on the surface of beta cell EVs. Treatment with IFN-α or IFN-γ for 24 h induced a twofold increase in EV PD-L1 cargo without a corresponding increase in the number of EVs. IFN exposure predominantly increased PD-L1 expression on the surface of beta cell EVs and beta cell EV PD-L1 showed a dose-dependent capacity to bind PD-1. Functional experiments demonstrated specific effects of beta cell EV PD-L1 to suppress proliferation and cytotoxicity of murine CD8+ T cells. Plasma EV PD-L1 levels were increased in Ab+individuals, particularly in those positive for a single autoantibody. Additionally, in Ab+ individuals or those who had type 1 diabetes, but not in control individuals, plasma EV PD-L1 positively correlated with circulating C-peptide, suggesting that higher EV PD-L1 could be protective for residual beta cell function. CONCLUSIONS/INTERPRETATION: IFN exposure increases PD-L1 on the beta cell EV surface. Beta cell EV PD-L1 binds PD1 and inhibits CD8+ T cell proliferation and cytotoxicity. Circulating EV PD-L1 is higher in Ab+ individuals than in control individuals. Circulating EV PD-L1 levels correlate with residual C-peptide at different stages in type 1 diabetes progression. These findings suggest that EV PD-L1 could contribute to heterogeneity in type 1 diabetes progression and residual beta cell function and raise the possibility that EV PD-L1 could be exploited as a means to inhibit immune-mediated beta cell death.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Rao C, Cater DT, Roy S, et al. Beta cell extracellular vesicle PD-L1 as a novel regulator of CD8+ T cell activity and biomarker during the evolution of type 1 diabetes. Diabetologia. 2024. PMID: 39508879. doi:10.1007/s00125-024-06313-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。